QIAGEN (QGEN)
(Delayed Data from NYSE)
$44.11 USD
-0.75 (-1.67%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $44.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Company Summary
Based in Venlo, the Netherlands, QIAGEN N.V. is one of the world’s leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of over 500 proprietary, consumable products, and automated solutions for sample collection.
Qiagen has subsidiaries in the United States, Germany, U.K., Switzerland, France, Japan, China, Australia, Canada, Norway, and several other countries with good sales potential.
Company Summary
Based in Venlo, the Netherlands, QIAGEN N.V. is one of the world’s leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of over 500 proprietary, consumable products, and automated solutions for sample collection.
Qiagen has subsidiaries in the United States, Germany, U.K., Switzerland, France, Japan, China, Australia, Canada, Norway, and several other countries with good sales potential.
Customer Classes:
QIAGEN focuses on two broad customer groups:Molecular Diagnostics (clinical testing) and Life Sciences (academia, pharmaceutical R&D and applied testing). In 2023, Molecular Diagnostics and Life Sciences comprised 52.7% and 47.3% of total sales respectively. The company estimates an addressable global market for its portfolio to be more than $11 billion.
Product Information:
QIAGEN’s products are grouped into two main categories: Consumables and related revenues (87.8% of 2023 net sales) include consumables kits, bioinformatics solutions, royalties, co-development milestone payments and services) and
Instruments and related services and contracts(12.2% of 2023 sales)
QIAGEN’s portfolio areas include:
Sample Technologies (includes consumables and instruments used in sample collection, stabilization, storage, purification and quality control).
Diagnostic Solutions (molecular testing platforms, consumables including QuantiFERON, QIAstat-Dx and NeuMoDx as well as Precision Diagnostics).
In the second quarter of 2024, the company decided to phase out the NeuMoDx clinical PCR system.
PCR / Nucleic Acid Amplification (research and applied PCR solutions and components including QIAcuity).
Genomics / NGS (universal NGS solutions and the full QIAGEN Digital Insights portfolio) and
Other (protein biology products, royalties, Intellectual properties and f
General Information
QIAGEN NV
HULSTERWEG 82
PL VENLO, P7 5912
Phone: 31-77-355-6600
Fax: 31-77-355-6658
Email: john.gilardi@qiagen.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.54 |
Current Year EPS Consensus Estimate | 2.15 |
Estimated Long-Term EPS Growth Rate | 6.50 |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 44.86 |
52 Week High | 47.44 |
52 Week Low | 34.74 |
Beta | 0.39 |
20 Day Moving Average | 1,452,795.38 |
Target Price Consensus | 52.23 |
4 Week | -2.52 |
12 Week | 10.22 |
YTD | 0.19 |
4 Week | -4.34 |
12 Week | 5.92 |
YTD | -16.64 |
Shares Outstanding (millions) | 228.20 |
Market Capitalization (millions) | 10,237.18 |
Short Ratio | NA |
Last Split Date | 1/25/2017 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 20.90 |
Trailing 12 Months | 21.61 |
PEG Ratio | 3.20 |
vs. Previous Year | 4.61% |
vs. Previous Quarter | 19.57% |
vs. Previous Year | 0.30% |
vs. Previous Quarter | 8.18% |
Price/Book | 3.01 |
Price/Cash Flow | 14.37 |
Price / Sales | 5.28 |
6/30/24 | 12.92 |
3/31/24 | 12.59 |
12/31/23 | 12.99 |
6/30/24 | 8.01 |
3/31/24 | 7.67 |
12/31/23 | 7.74 |
6/30/24 | 1.77 |
3/31/24 | 1.84 |
12/31/23 | 1.99 |
6/30/24 | 1.46 |
3/31/24 | 1.45 |
12/31/23 | 1.62 |
6/30/24 | 24.16 |
3/31/24 | 23.91 |
12/31/23 | 24.26 |
6/30/24 | 3.75 |
3/31/24 | 17.38 |
12/31/23 | 17.37 |
6/30/24 | 5.03 |
3/31/24 | 21.83 |
12/31/23 | 21.87 |
6/30/24 | 14.92 |
3/31/24 | 15.77 |
12/31/23 | 16.69 |
6/30/24 | 2.63 |
3/31/24 | 1.81 |
12/31/23 | 1.86 |
6/30/24 | 0.27 |
3/31/24 | 0.25 |
12/31/23 | 0.24 |
6/30/24 | 21.07 |
3/31/24 | 20.23 |
12/31/23 | 19.49 |